{
  "docId": "019de074-71be-772a-8bed-f9d5eaece76b",
  "docSlug": "e4f10758c80bf7a23f09bd201ccd4281",
  "documentTitle": "Alkermes | Investor Presentation Deck | 32 slides",
  "authorId": "alkermes",
  "authorName": "Alkermes",
  "documentKindSlug": "research-note",
  "documentKindLabel": "Research note",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 4,
  "pageCount": 32,
  "prevPage": 3,
  "nextPage": 5,
  "slideType": "propose_solution",
  "function": "present_solution",
  "density": "sparse",
  "nDataPoints": 0,
  "notes": "The slide uses a hub-and-spoke diagram to show the core Alkermes business assets and the spin-off oncology business.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-71be-772a-8bed-f9d5eaece76b/4",
  "deckHref": "/decks/019de074-71be-772a-8bed-f9d5eaece76b",
  "deckJsonHref": "/decks/019de074-71be-772a-8bed-f9d5eaece76b.json",
  "deckAnchorHref": "/decks/019de074-71be-772a-8bed-f9d5eaece76b#slide-4",
  "components": [
    {
      "bbox": {
        "h": 0.7,
        "w": 0.85,
        "x": 0.1,
        "y": 0.2
      },
      "kind": "diagram",
      "text": "Alkermes hub with spokes for commercial products, infrastructure, royalties, manufacturing, and neuroscience R&D, plus a separate oncology node.",
      "attrs": null,
      "subkind": "hub-spoke",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bf20603d-6d99-4c7f-aba2-ed9390271638",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.7,
        "x": 0.05,
        "y": 0.88
      },
      "kind": "disclaimer",
      "text": "*VUMERITY is licensed to and commercialized exclusively by Biogen\n**Assuming separation of the company's oncology business is effected through a spin-off of the oncology business into an independent, publicly-traded company",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5f7e59e5-872f-4f61-b076-7dc6727c9663",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.6,
        "x": 0.05,
        "y": 0.07
      },
      "kind": "title",
      "text": "Post-Separation: Clear Value Propositions in Neuroscience and Oncology",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b07f7a7f-89a8-44be-aae5-f9ad49275810",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "2x2 matrix",
      "slug": "matrix-2x2",
      "agent": null,
      "layer": "slide",
      "matchId": "db359850-a112-4d37-a3c8-baf94b06d7ba",
      "evidence": "diagram/hub-spoke: Alkermes hub with spokes for commercial products, infrastructure, royalties, manufacturing, and neuroscience R&D, plus a separate oncology node.",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "breakup-spinoff",
      "slug": null,
      "matchId": "17aa2530-b2ec-4622-8b13-93f8a9466ef0",
      "evidence": "The slide explicitly discusses the separation of the oncology business into an independent company.",
      "confidence": 1
    }
  ],
  "arcBeats": [
    {
      "to": 4,
      "from": 4,
      "beatId": "587708dd-c570-423a-bf1c-47d928f68456",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Solution & Approach",
      "beatSlug": "consultants-gambit-solution-approach",
      "evidence": "Post-Separation: Clear Value Propositions in Neuroscience and Oncology",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 5,
      "from": 3,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "c9281d04-7074-4aa0-aa00-07c1fd5214a7",
      "evidence": "Alkermes Today, Clear Priorities to Unlock Value in 2023",
      "position": 0,
      "objective": "why Alkermes is a good investment",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.8,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}